Skip to the content
logo mainlogo darklogo light
  • About
    • Leadership Team
    • Scientific & Clinical Advisors
    • Board of Directors
    • Collaborations & Partnerships
  • Technology
  • Product Pipeline
    • EO-1001 Program
    • EO-3001 Program
    • EO-4426 Program
    • OROTECAN Program
  • News & Media
    • Press Releases
    • Presentations & Publications
  • Contact
  • Careers
logo mainlogo darklogo light
Press Releases
Presentations & Publications

Presentations & Publications

Home
News & Media
Presentations & Publications
Written by Edison Oncology
August 1, 2022
Presentations and Publications

A Phase 1-2 clinical trial of EO1001, a novel irreversible pan-ErbB inhibitor with promising brain penetration

1 min read
Read More
Written by Edison Oncology
June 1, 2022
Presentations and Publications

An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and antitumor activity of once-daily oral treatment with EO1001 – a novel irreversible pan-ErbB inhibitor with promising brain penetration – in patients with advanced cancer

1 min read
Read More
Written by Edison Oncology
June 1, 2022
Presentations and Publications

A Pilot Pharmacokinetic Clinical Study of VAL-413 (Orotecan®) in Patients with Recurrent Pediatric Solid Tumors

1 min read
Read More
Written by Edison Oncology
January 4, 2020
Presentations and Publications

EO1001: A first-in-class irreversible pan-ErbB inhibitor with excellent brain penetration

1 min read
Read More
Written by Edison Oncology
August 4, 2019
Presentations and Publications

Preclinical development of EO1001, a novel irreversible brain penetrating pan-ErbB inhibitor (Oral Presentation)

1 min read
Read More

Company

  • Leadership Team
  • About
  • Careers

Information

  • Technology
  • Product Pipeline
  • Press Releases

Menlo Park, CA

  • 3475 Edison Way,
    Suite R
    Menlo Park, CA 94025

© 2025 Edison Oncology, All Rights Reserved

Back to top Drag
  • About
    • Leadership Team
    • Scientific & Clinical Advisors
    • Board of Directors
    • Collaborations & Partnerships
  • Technology
  • Product Pipeline
    • EO-1001 Program
    • EO-3001 Program
    • EO-4426 Program
    • OROTECAN Program
  • News & Media
    • Press Releases
    • Presentations & Publications
  • Contact
  • Careers

John K. Bell

Independent Board Member

John K. Bell serves as lead independent director and chair of the audit committee.

Mr. Bell is the founder of Shred-Tech Ltd. and Polymer Technologies, Inc., John K. Bell is a businessperson who has been the head of 15 different companies and presently is Chairman at CrossChasm Technologies, Inc., Chairman & Chief Executive Officer at Onbelay Investment Corp., Chairman for Stack Capital Group, Inc., lead independent director of Edison Oncology Holding Corp., and Director & Governor at Stratford Festival. He is also on the board of Stratford Shakespearean Festival of America.

Mr. Bell was a founding investor of Research in Motion (Blackberry) and previously held the position of Director at Canopy Growth Corp. and Chairman of Canopy Rivers Corp. (a subsidiary of Canopy Growth Corp.), Chairman of Waterloo Regional Police Service, Chairman of Prosperity Council of Waterloo Region, Director at RIV Capital, Inc., Chief Executive Officer & Director at ATS Corp., Chief Executive Officer & Owner at Shred-Tech Ltd., Director at BSM Technologies, Inc., Director at BSM Technologies Ltd., Chairman of HEXO Corp., President & Chief Executive Officer of Polymer Technologies, Inc., Chairman of Cambridge Memorial Hospital, Member of Institute of Corporate Directors and Secretary & Director at Crohn’s & Colitis Foundation of Canada.

John K. Bell received an undergraduate degree from Richard Ivey School of Business.